Insider · CIK 0001420482
Mark W Frohlich
Files at RIGL (RIGEL PHARMACEUTICALS INC). First filing -, latest -.
In brief
Mark W Frohlich files SEC Form 4 as director at RIGL (RIGEL PHARMACEUTICALS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark W Frohlich has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Common Stock | +5,750 | $0.00 | $0 | 7,000 | May 19, 2026 |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 1,250 | May 28, 2025 |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Stock Option (Right to Buy)derivative | +1,500 | $0.00 | $0 | 1,500 | May 28, 2025 |
| Mar 6, 2025 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | Mar 10, 2025 |
Questions about Mark W Frohlich
Answered from the filings on this page, as of the latest one.
Is Mark W Frohlich buying or selling?
Mark W Frohlich has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark W Frohlich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark W Frohlich has 0.
Where does Mark W Frohlich file Form 4?
Mark W Frohlich has filed Form 4 at RIGL (RIGEL PHARMACEUTICALS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.